An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Condition:   Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Intervention:   Drug: Dacomitinib Sponsor:   Guangdong Association of Clinical Trials Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials